시간 외 거래: 9.02

Newamsterdam Pharma Company N V (NAMSW)

개요 뉴스 가격 이력 Financials 토론 예측

Newamsterdam Pharma Company N V 주식(NAMSW)의 최신 뉴스

Newamsterdam Pharma Company N V (NAMSW)

Newamsterdam Pharma Company N V 주식(NAMSW)의 최신 뉴스

NewAmsterdam Pharma's (NAMS) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

NewAmsterdam Pharma target raised to $45 on strong trial data - Investing.com

Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online

NewAmsterdam Pharma target raised to $45 on strong trial data By Investing.com - Investing.com UK

NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times

NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com

Trend Tracker for (NAMSW) - Stock Traders Daily

Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times

RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com

GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St

When the Price of (NAMS) Talks, People Listen - Stock Traders Daily

Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World

William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat

Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat

Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World

Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World

(NAMSW) Proactive Strategies - Stock Traders Daily

What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat

NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga

Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat

NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan

abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

Latest Company News - Investing.com UK

(NAMSW) Trading Report - Stock Traders Daily

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN

Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily

Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha

NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa

NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat

NewAmsterdam Pharma Company NV (NAMS) rating initates by TD Cowen - Knox Daily

Does NewAmsterdam Pharma Company NV (NAMS) offer a good opportunity for investors? - SETE News

NAMSW과 유사한 종목